Advertisement

Topics

Agilent Technologies, Agendia ink molecular cancer diagnostics agreement

13:09 EDT 5 Jun 2017 | CentreWatch

Agilent Technologies and Agendia jointly announced an agreement to expand their relationship to include the development of an RNA-Seq kit version of Agendia’s currently marketed MammaPrint and BluePrint tests. Agendia’s MammaPrint test provides High-Risk or Low-Risk test results to assess the risk of distant metastasis within five years, in breast cancer patients with Stage I […]

The post Agilent Technologies, Agendia ink molecular cancer diagnostics agreement appeared first on CenterWatch News Online.

Original Article: Agilent Technologies, Agendia ink molecular cancer diagnostics agreement

NEXT ARTICLE

More From BioPortfolio on "Agilent Technologies, Agendia ink molecular cancer diagnostics agreement"

Quick Search
Advertisement
 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...